Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31629437 | 1.00 | CTSL (0.44) | CTSLCTSBCTSKAGTR2BCHE | |
| SCHEMBL19403046 | 0.86 | BCHE (0.43) | CTSLCTSBCTSKAGTR2BCHE | |
| SCHEMBL31629597 | 0.84 | TSHR (0.42) | BCHEALDH1A1EPHX2 | |
| SCHEMBL14478947 | 0.84 | BCHE (0.51) | CTSLCTSBCTSKBCHEALDH1A1 | |
| SCHEMBL14478960 | 0.81 | BCHE (0.46) | CTSLCTSBCTSKBCHEALDH1A1 | |
| SCHEMBL402480 | 0.81 | BCHE (0.46) | CTSLCTSBCTSKBCHEALDH1A1 | |
| SCHEMBL31629581 | 0.79 | CTSL (0.38) | CTSLCTSBCTSKAGTR2BCHE | |
| SCHEMBL31629578 | 0.79 | CTSL (0.38) | CTSLCTSBCTSKAGTR2BCHE | |
| SCHEMBL52862 | 0.77 | ALDH1A1 (0.44) | CTSLCTSBCTSKAGTR2BCHE | |
| SCHEMBL19403042 | 0.77 | CTSL (0.45) | CTSLCTSBCTSKAGTR2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9980948-B2 | Azaindole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20170273955-A1 | AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273955-A1 | AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAA1, PRKAA2, PRKAG1 | CTSL 2733/4885CTSB 3473/4885CTSK 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.